Clinical Trial Detail

NCT ID NCT03777657
Title Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors BeiGene
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Capecitabine + Oxaliplatin

Cisplatin + Fluorouracil

Capecitabine + Oxaliplatin + Tislelizumab

Cisplatin + Fluorouracil + Tislelizumab

Age Groups: adult senior

Additional content available in CKB BOOST